Exegenesis Bio and Modalis sign collaboration to advance MDL-201
Exegenesis Bio and Modalis Therapeutics Corporation announced a research collaboration and license agreement to advance MDL-201 for Duchenne muscular dystrophy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.